Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention. We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease (CVD) prevention in clinical practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global CVD risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-Cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (Step 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After Step 1, considering proceeding to the intensified goals of Step 2 is mandatory, and this intensification will be based on 10-year CVD risk, lifetime CVD risk and treatment benefit, comorbidities and patient preferences. The updated SCORE algorithm-SCORE2, SCORE-OP- is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal CVD events (myocardial infarction, stroke) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according different age groups (< 50, 50-69 ≥ 70 years). Different flow charts of CVD risk and risk factor treatment in apparently healthy persons, in patients with established atherosclerotic CVD, and in diabetic patients are recommended. Patients with chronic kidney disease are considered high risk or very high-risk patients according to the levels of glomerular filtration rate and albumin-to-creatinine ratio. New lifestyle recommendations adapted to the ones published by the Spanish Ministry of Health as well as recommendations focused on the management of lipids, blood pressure, diabetes and chronic renal failure are included.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hipert.2022.02.003 | DOI Listing |
JAMA Intern Med
January 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Importance: Evidence on cardiovascular benefits and safety of sodium-glucose cotransporter 2 (SGLT-2) inhibitors is mainly from placebo-controlled trials. Therefore, the comparative effectiveness and safety of individual SGLT-2 inhibitors remain unknown.
Objective: To compare the use of canagliflozin or dapagliflozin with empagliflozin for a composite outcome (myocardial infarction [MI] or stroke), heart failure hospitalization, MI, stroke, all-cause death, and safety outcomes, including diabetic ketoacidosis (DKA), lower-limb amputation, bone fracture, severe urinary tract infection (UTI), and genital infection and whether effects differed by dosage or cardiovascular disease (CVD) history.
Crit Pathw Cardiol
January 2025
Internal Medicine Department, College of Medicine, King Faisal University, Alhasa, Saudi Arabia.
Introduction: Cardiovascular diseases (CVDs) are the principal cause of worldwide mortality, with 17.9 million deaths reported in 2019. In Saudi Arabia, CVDs account for 42% of all deaths, occurring on average 10 years earlier than in Western populations.
View Article and Find Full Text PDFHeliyon
January 2025
Center for Applied Intelligent Systems Research, Halmstad University, Sweden.
The influence of the exposome on major health conditions like cardiovascular disease (CVD) is widely recognized. However, integrating diverse exposome factors into predictive models for personalized health assessments remains a challenge due to the complexity and variability of environmental exposures and lifestyle factors. A machine learning (ML) model designed for predicting CVD risk is introduced in this study, relying on easily accessible exposome factors.
View Article and Find Full Text PDFBackground: Trimethylamine N-oxide (TMAO), a metabolite dependent on intestinal microbiota, is closely related to the emergence, progression, and prognosis of cardiovascular disease (CVD), and has received increasing attention in recent years.
Objective: The current research hotspots and future development trends in TMAO and CVD field are found through bibliometrics analysis, which provides reference for further study.
Methods: The bibliometrics tools VOSviewer and CiteSpace were used to analyze the publications from the Web of Science Core Collection (WOSCC) database.
AIDS Res Treat
January 2025
Department of Biomedical Sciences, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Atherogenic index of plasma (AIP) and high-sensitivity C-reactive protein (hsCRP) levels which are strong predictors of the risk of cardiovascular disease (CVD) seen elevated in the serum of people living with HIV (PLWH) on HAART and in those with low cluster of differentiation-4 (CD4) cell counts. Thus, this study aimed to evaluate AIP and hsCRP levels among PLWH on dolutegravir (DTG) and ritonavir-boosted atazanavir-based (ATV/r) antiretroviral therapy (ART) and their correlations to CD4 cell counts. The study design was an institutional-based comparative cross-sectional study conducted from November 4, 2021, to January 4, 2022.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!